[Cancer Research 62, 5902-5905, October 15, 2002]
© 2002 American Association for Cancer Research
Molecular Biology and Genetics |
Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer1
Manel Esteller,
Mingzhou Guo,
Victor Moreno,
Miquel Angel Peinado,
Gabriel Capella,
Oliver Galm,
Stephen B. Baylin and
James G. Herman2
The Johns Hopkins Oncology Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21231 [M. E., M. G., O. G., S. B. B., J. G. H.]; Cancer Epigenetics Laboratory, Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas, Majadahonda, 28220 Madrid, Spain [M. E.]; Institut Català d’Oncologia and Laboratori de Bioestadística i Epidemiologia, Universitat Autònoma de Barcelona, 08907 Catalonia, Spain [V. M.]; Institut de Recerca Oncològica, Ciutat Sanitària Universitària de Bellvitge, L’Hospitalet, Barcelona, 08907 Catalonia, Spain [M. A. P.]; and Institut Català d’Oncologia, Hospital Duran i Reynals, L’Hospitalet, Barcelona, 08907 Catalonia, Spain [G. C.]
 |
ABSTRACT
|
|---|
The effects of retinol (vitamin A) depend on its transport and binding to nuclear receptors. The cellular retinol-binding protein 1 (CRBP1) and the retinoic acid receptor ß2 (RARß2) are key components of this process. Loss of CRBP1 expression occurs in breast tumors, but the mechanism is not known. We examined whether CpG island hypermethylation of CRBP1 was responsible for its inactivation in cancer cell lines (n = 36) and primary tumors (n = 553) and its relation to RARß2 methylation. Hypermethylation of CRBP1 was common in tumors and cancer cell lines, with the highest frequency in lymphoma and gastrointestinal carcinomas. Hypermethylation correlated with loss of CRBP1 mRNA, and in vitro treatment with the demethylating agent 5-aza-2'-deoxycytidine reactivated CRBP1 expression. CRBP1 methylation appeared in premalignant lesions and frequently occurred with RARß2 hypermethylation in the same tumors. Finally, we observed that a higher dietary retinol intake was associated with reduced frequencies of methylation of both genes. Epigenetic disruption of CRBP1 is a common event in human cancer that may have important implications for cancer prevention and treatment using retinoids.
|
INTRODUCTION
|
|---|
Retinoids, analogues of vitamin A, are known to control cellular signals involved in cell growth, differentiation, and carcinogenesis (1
, 2)
. Retinoids suppress preneoplastic lesions and prevent the development of second primary cancers (3
, 4)
. 9-cis-Retinoic acid inhibits mammary tumors induced by N-nitroso-N-methylurea (5)
. However, some tumors show resistance to retinoid action by mechanisms still largely unknown. Retinoid activity is mediated by nuclear hormone receptors. The RARs3
, ß, and 
and RXRs , ß, and act as ligand-activated transcription factors. Disruption of RARs and RXRs results in developmental defects and neoplastic transformation (1
, 2)
. Aberrant retinoid signaling in cancer has been found in the leukemogenic role of the dominant-negative PML-RAR fusion protein in acute promyelocytic leukemia (6)
and the demonstration of down-regulation of RARß2 expression in solid human carcinomas (7, 8, 9)
caused by CpG island promoter hypermethylation and loss of heterozygosity (10, 11, 12, 13)
.
Other key components in retinoid activity are the CRBPs. The CRBPs belong to the family of fatty acid-binding proteins, and three members have been described: CRBP2 and CRBP3, which show tissue-specific expression (14
, 15)
; and CRBP1, which is expressed widely (16)
. Retinoic acid (the main active metabolite of retinol) is present in the circulation, but most tissues rely on the uptake and cytosolic metabolism of retinol to activate RARs and RXRs. CRBPs possess a high-affinity binding for retinol, possibly functioning as a chaperone-like molecule to regulate this prenuclear phase of retinol signaling (14)
. Furthermore, the critical role of CRBP1 is demonstrated in the CRBP1 knock-out mice, which are very susceptible to hypovitaminosis A syndrome (17)
. Recently, CRBP1 down-regulation in breast cancer cell lines (8)
and tumors (18)
has been observed. The mechanism behind this inactivation has not been established. We investigated the possible role of CpG island aberrant methylation in CRBP1 silencing and its relationship to RARß2 methylation and dietary retinol intake.
|
MATERIALS AND METHODS
|
|---|
Cell Lines and Tumor Samples.
The cancer cell lines used in this study were MCF-7, MDA-MB-231, MDA-MB-468, T47D, Hs578, MDA-435 (breast); SW48, DLD1, RKO, SW837, HCT-116, SW480, Colo-320, HT29 (colon); H358, H1618, H249, H209, H157, H460, H69, DMS53, A549, H1299, H1752 (lung); DuPro, LnCAP, PC3, Dn145 (prostate); UMSCC1, HN12 (head and neck); D283, DaOY (glioma); Raji (lymphoma), KG1a (leukemia); HeLa (cervix); and T24 (bladder). Cell lines were maintained in appropriate medium and treated with demethylating agent 5-aza-2'-deoxycytidine as described (19)
. Primary malignancies were obtained at the Johns Hopkins Hospital in Baltimore, MD and the Hospitals Sant Pau and Duran i Reynals in Barcelona, Spain and have been examined for other epigenetic changes (19, 20, 21)
. For 131 colorectal cancer patients, dietary history was obtained according to the following cohort design. These were among the patients consecutively diagnosed and operated at the Hospital Duran i Reynals during 1996 that provided informed consent, biological specimens to extract DNA, and completed the questionnaires. They were interviewed after diagnosis, usually within 15 days before or after surgical removal of the tumor. The interview was carried out by trained personnel using a structured questionnaire to avoid potential recall biases on epidemiological factors and a dietary history based on the average food consumption 1 year previous to the disease (22)
. Nutrient intakes (retinol and carotene) were estimated using food composition tables. To adjust for total energy intake, nutrient densities were calculated dividing nutrient intake by total kilocalories estimated from macronutrients plus alcohol (23)
.
Analysis of CRBP1 and RARß2 Promoter Methylation Patterns.
DNA methylation patterns in the CpG island of CRBP1 were determined by methylation-specific PCR (24)
. Methylation-specific PCR distinguishes unmethylated from methylated alleles in a given gene on the basis of sequence changes produced after bisulfite treatment of DNA, which converts unmethylated, but not methylated, cytosines to uracil and subsequent PCR by use of primers designed for either methylated or unmethylated DNA (24)
. Primer sequences of CRBP1 for the unmethylated reaction were 5'-GTGTTGGGAATTTAGTTGTTGTTGTTTT-3' (sense) and 5'-ACTACCAAAACAACAACTACCAATACTACA-3' (antisense); and for the methylated reaction, 5'-TTGGGAATTTAGTTGTCGTCGTTTC-3' (sense) and 5'-AAACAACGACTACCGATACTACGCG-3' (antisense). Primers for RARß2 were: unmethylated reaction, 5'-TTGGGATGTTGAGAATGTGAGTGATTT-3' (sense) and 5'-CTTACTCAACCAATCCAACCAAAACAA-3' (antisense); and for the methylated reaction, 5'-TGTCGAGAACGCGAGCGATTC-3' (sense) and 5'-CGACCA ATCCAACCGAAACGA-3' (antisense).
RT-PCR of CRBP1.
RT-PCR was performed as described previously (18
, 19)
. The PCR primers used were 5'-TTGTGGCCAAACTGGCTCCA-3' (sense) for exon 1 and 5'-ACACTGGAGCTTGTCTCCGT-3' (antisense) for exon 3 of CRBP1, which amplify a 320-bp product. Glyceraldehyde-3-phosphate dehydrogenase served as a positive control (19)
.
Statistical Analysis.
All comparisons for statistical significance were performed by use of 
2 or Fisher’s exact test, as appropriate, with all Ps representing two-tailed tests and statistically significant at 0.05. For the cases where dietary information was collected, binary logistic regression models adjusted for age and sex were developed. Retinol and carotene intakes were categorized into quartiles to avoid the effect of extreme values. OR and 95% confidence intervals were calculated for quartiles 2 to 4 compared with the first one. Tests for linear trend on the ORs were calculated using the categorized variable as quantitative.
|
RESULTS
|
|---|
Promoter Hypermethylation and Expression of CRBP1 in Normal Tissues and Cancer Cell Lines.
CRBP1 is a candidate for hypermethylation-associated inactivation because a 5'-CpG island is located around the transcription start site. All normal tissues analyzed, including lymphocytes, breast, colon, bone marrow, endometrium, kidney, liver, and lung, were completely unmethylated at the CRBP1 promoter (Fig. 1A)
. The CRBP1 CpG island was fully methylated in 17 of 37 cancer cell lines studied: MCF-7, MDA-MB-231, T47D, Hs578, MDA-MB-435, SW48, DLD1, RKO, SW837, DuPro, LnCAP, PC3, Dn145, H358, D283, RAJI, and KG1a (examples in Fig. 1B
). Two lung cancer cell lines were partially methylated (H1299 and H1752). The remaining 17 cell lines were unmethylated at the CRBP1 promoter. Expression of the CRBP1 transcript was assessed by RT-PCR in several cell lines. The cell lines MDA-MB-231, MCF-7, SW837, SW48, and Dn145, hypermethylated at the CRBP1 promoter, did not express CRBP1, whereas MDA-MB-468, normal lymphocytes, and normal colon, unmethylated at the CRBP1 promoter, had strong CRBP1 expression. The treatment of the methylated cancer cell lines with the demethylating agent 5-aza-2'-deoxycytidine restored the expression of the CRBP1 transcript (Fig. 1C)
.
View larger version (47K):
[in this window]
[in a new window]
|
Fig. 1. Analysis of CRBP1 methylation and expression in normal tissues and cancer cell lines. The presence of a visible PCR product in Lanes U indicates the presence of unmethylated genes of CRBP1; the presence of product in Lanes M indicates the presence of methylated genes. Placental DNA treated in vitro with SssI methylase (IVD) was used as a positive control for CRBP1 promoter hypermethylation, and normal lymphocytes (NL) were used as negative control for methylation. Water controls for PCR reactions are also shown. A, methylation-specific PCR of CRBP1 in normal tissues: lung (NLu), breast (NB), colon (NC), endometrium (NE), kidney (NK), and liver (NLi). B, methylation-specific PCR of CRBP1 in cancer cell lines. MDA-MB-468 is fully unmethylated at CRBP1, and MDA-MB-231 and SW48 are fully methylated. The reappearance of unmethylated alleles is observed in those cell lines treated with the demethylating agent 5-aza-2'-deoxycytidine (MDA-MB-231 AZA and SW 48 AZA). In C, the pattern of expression was determined by RT-PCR of the CRBP1 transcript in cancer cell lines before and after 5-aza-2'-deoxycytidine treatment and in normal lymphocytes and colon. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression demonstrates equal amounts of initial mRNA.
|
|
Promoter Hypermethylation of CRBP1 in Human Primary Tumors.
To assess the prevalence of promoter hypermethylation of CRBP1 in vivo, we examined 553 human primary tumors. The highest incidence of CRBP1 promoter hypermethylation was found in non-Hodgkin’s lymphomas, where 39 of 65 (60%) had CRBP1 epigenetic inactivation (examples in Fig. 2
). Among different histological subtypes of lymphoma, CRBP1 aberrant methylation was present in 24 of 39 (62%) diffuse, 5 of 9 (56%) follicular, 2 of 2 (100%) Burkitt’s, and 8 of 15 (53%) lymphomas of other histologies.
View larger version (41K):
[in this window]
[in a new window]
|
Fig. 2. CRBP1 promoter hypermethylation in human cancer using methylation-specific PCR. A, non-Hodgkin’s lymphoma samples (Ly1 to Ly 6). B, colorectal carcinomas (C1 to C7). C, leukemia samples (Le1 to Le6). D, gastric carcinomas (G1 to G7). In vitro methylated DNA (IVD) was used as a positive control for CRBP1 promoter hypermethylation, and normal lymphocytes (NL) were used as a negative control for methylation. Water controls for PCR reactions are also shown.
|
|
Aberrant CpG island methylation of the CRBP1 was also common in colorectal (57%; 101 of 177), gastric (42%; 8 of 19), and liver (30%; 10 of 33) tumors, as well as leukemia samples (28%; 15 of 53). Additionally, CRBP1 hypermethylation was also observed in breast (19%; 9 of 48), bladder (18%; 5 of 27), non-small cell lung (15%; 6 of 41), glioma (14%; 3 of 21), and head and neck (7%; 1 of 15) tumors. No CRBP1 promoter methylation was observed in endometrial (0 of 33) or ovarian (0 of 21) tumors. The data are summarized in Table 1
.
View this table:
[in this window]
[in a new window]
|
Table 1 Patterns of CRBPI promoter hypermethylation in human cancer according to the prevalence of the alteration
|
|
Promoter Hypermethylation and Expression of CRBP1 in Preneoplastic Lesions.
To further address the relevance of CRBP1 hypermethylation, we examined CRBP1 methylation in preinvasive lesions of the gastrointestinal tract. CRBP1 promoter hypermethylation was observed in 21 of 34 (62%) colorectal adenomas (Fig. 3A)
and 13 of 21 (62%) gastric adenomas. This rate is similar to the percentage found in the invasive colorectal and gastric tumors and suggests that methylation-associated inactivation of CRBP1 is an early event in human tumorigenesis. To confirm that the methylation of this 5' region of the CRBP1 gene was functionally relevant, we examined the expression of CRBP1 using RT-PCR in 8 colorectal adenomas. Five colorectal adenomas without CRBP1 methylation expressed high levels of CRBP1 mRNA, whereas all 3 adenomas with CRBP1 aberrant methylation had undetectable CRBP1 transcript (Fig. 3B)
.
View larger version (48K):
[in this window]
[in a new window]
|
Fig. 3. Analysis of CRBP1 methylation and expression in premalignant lesions. A, methylation-specific PCR of CRBP1 in colorectal adenomas (A1 to A7). B, corresponding pattern of expression of CRBP1 by RT-PCR in the adenomas shown above. The colorectal adenomas A3, A5, and A7 with CRBP1 aberrant methylation show loss of expression of the CRBP1. Water controls for PCR reaction are also shown.
|
|
Relationship of CRBP1 Aberrant Methylation to RARß2 Promoter Hypermethylation.
Because alteration of the RARß2 gene is common in human malignancies (10, 11, 12, 13)
, we wondered whether any relationship between methylation of RARß2 and CRBP1 existed. Similar to CRBP1, we found that hypermethylation of the RARß2 promoter was also a common event in colon cancer (54%; 93 of 172) and non-Hodgkin’s lymphoma (26%; 11 of 42). The most common group observed was those tumors where both genes were concomitantly methylated, 39% (84 of 214), but closely followed for the category where both were unmethylated, 30% (65 of 214). In 20% (43 of 214) of cases, CRBP1 was hypermethylated alone, and only in a minority of cases, 10% (22/214), RARß2 was hypermethylated alone. No significant differences between colon tumors and lymphomas were observed. Thus, both genes were simultaneously hypermethylated more often than expected by chance (Kappa statistic P < 0.0001), although RARß2 was methylated more often than CRBP1 (Exact McNemar test, P = 0.013).
Dietary Intake of Retinoids and Its Relation to CRBP1 and RARß2 Methylation Patterns and Colorectal Cancer Risk.
For 131 colorectal cancer patients, a dietary history was available as described in "Materials and Methods." Median daily retinol intake in these patients was 155 µg (interquartile range, 102 to 239). These values were used as cutpoints to define quartiles. We found that cases in the highest quartile of retinol intake were more likely to have CRBP1 and RARß2 unmethylated. The ORs were 1.9 (P for linear trend = 0.069) for CRBP1 and 2.5 (P for linear trend = 0.039) for RARß2. Other nutrients analyzed and found unrelated to the methylation status of the genes were vitamin C, E, lycopene, lutein, -carotene, and ß-carotene. The methylation status of CRBP1 was also unrelated to age, sex, or stage at diagnosis in this sample of subjects.
|
DISCUSSION
|
|---|
Our data demonstrate that epigenetic disruption of CRPBI is a common event in human cancer. The first described alteration in the retinoid pathway was the leukemogenic role of the PML-RAR fusion protein (6)
. Later, evidence supported the role of RARß2 as a tumor suppressor gene: the induction of RARß2 related to the chemopreventive effects of retinoids (25)
, the loss of RARß2 expression in human neoplasms (7
, 9)
, frequent chromosomal losses at 3p21–3p24 where RARb2 is located (26
, 27)
, and the methylation-mediated silencing of RARß2 (10
, 13)
. We now provide another piece of this puzzle; the epigenetic silencing of CRBP1 is also a common alteration in human cancer.
What are the biological consequences of the methylation-mediated silencing of CRBP1? The loss of CRBP1 may compromise retinoic acid metabolism by diminishing retinol transport and blocking the formation of retinyl esters (14
, 28)
. Interestingly, it has also been demonstrated that the lack of retinoic acid function may increase the activity of the ß-catenin-LEF/T-cell factor signaling pathway (29)
, a central element in malignant cell transformation. Our data also show the relatively common simultaneous inactivation of CRBP1 and RARß2. One explanation is that CRBP1 may have a function independent of its retinol-binding ability. In this regard, CRBP1 also functions in mammary epithelial cell inhibition of the phosphatidylinositol 3-kinase/Akt survival pathway and suppresses anchorage-independent growth (30)
.
In addition, aberrant methylation of CRBP1 may have predictive value. Until now, the use of retinoids to prevent or treat human cancer has achieved only modest success (31)
. The disruption of CRBP1 and RARß2 by promoter hypermethylation in many of the human neoplasms may in part explain this resistance. However, in colorectal tumors, 
30% of malignancies did not present any apparent lesion in the retinoid pathway. This subset of tumors may be extremely sensitive to treatment with retinoids.
|
FOOTNOTES
|
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 Supported by the Health Department of the Spanish Government, Grant I+D+I SAF 2001-0059; National Cancer Institute Grants CA84986, CA58184 and CA88843; and the International Rett Syndrome Association. 
2 To whom requests for reprints should be addressed, at The Johns Hopkins Comprehensive Cancer Center, Room 543, 1650 Orleans Street, Baltimore, MD 21231. Phone: (410) 955-8506; Fax: (410) 614-9884; E-mail: hermanji{at}jhmi.edu
3 The abbreviations used are: RAR, retinoic acid receptor; RXR, retinoid X receptor; CRBP1, cellular retinol-binding protein 1; RT-PCR, reverse transcription-PCR; OR, odds ratio.
Received 4/11/02.
Accepted 8/16/02.
|
REFERENCES
|
|---|
- Gudas L. J. Retinoids and vertebrate development. J. Biol. Chem., 269: 15399-15402, 1994.[Abstract/Free Full Text]
- Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J., 10: 940-954, 1996.[Abstract]
- Hong K. W., Lippman S. M., Hittelman W. N., Lotan R. Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. Clin. Cancer Res., 1: 677-686, 1995.[Abstract]
- Pastorino U., Infante M., Maioli M., Chiesa G., Buyse M., Firket P., Rosmentz N., Clerici M., Soresi E., Valente M. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J. Clin. Oncol., 11: 1216-1222, 1993.[Abstract/Free Full Text]
- Anzano M. A., Peer C. W., Smith J. M., Mullen L. T., Shrader M. W., Logsdon D. L., Driver C. L., Brown C. C., Roberts A. B., Sporn M. B. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J. Natl. Cancer Inst., 88: 123-125, 1996.[Free Full Text]
- Melnick A., Licht J. D. Deconstructing a disease: RAR, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood, 93: 3167-3215, 1999.[Free Full Text]
- Picard E., Seguin C., Monhoven N., Rochette-Egly C., Siat J., Borrelly J., Martinet Y., Martinet N., Vignaud J. M. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J. Natl. Cancer Inst., 91: 1059-1066, 1999.[Abstract/Free Full Text]
- Jing Y., Zhang J., Bleiweiss I. J., Waxman S., Zelent A., Mira-Y-Lopez R. Defective expression of cellular retinol binding protein type I and retinoic acid receptors 2, ß2, and 2 in human breast cancer cells. FASEB J., 10: 1064-1070, 1996.[Abstract]
- Xu X. C., Sneige N., Liu X., Nandagiri R., Lee J. J., Lukmanji F., Hortobagyi G., Lippman S. M., Dhingra K., Lotan R. Progressive decrease in nuclear retinoic acid receptor ß messenger RNA level during breast carcinogenesis. Cancer Res., 57: 4992-4996, 1997.[Abstract/Free Full Text]
- Bovenzi V., Le N. L., Cote S., Sinnett D., Momparler L. F., Momparler R. L. DNA methylation of retinoic acid receptor ß in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs, 10: 471-476, 1999.[Medline]
- Virmani A. K., Rathi A., Zochbauer-Muller S., Sacchi N., Fukuyama Y., Bryant D., Maitra A., Heda S., Fong K. M., Thunnissen F., Minna J. D., Gazdar A. F. Promoter methylation and silencing of the retinoic acid receptor-ß gene in lung carcinomas. J. Natl. Cancer Inst., 92: 1303-1307, 2000.[Abstract/Free Full Text]
- Arapshian A., Kuppumbatti Y. S., Mira-y-Lopez R. Methylation of conserved CpG sites neighboring the ß retinoic acid response element may mediate retinoic acid receptor ß gene silencing in MCF-7 breast cancer cells. Oncogene, 19: 4066-4070, 2000.[Medline]
- Widschwendter M., Berger J., Hermann M., Muller H. M., Amberger A., Zeschnigk M., Widschwendter A., Abendstein B., Zeimet A. G., Daxenbichler G., Marth C. Methylation and silencing of the retinoic acid receptor-ß2 gene in breast cancer. J. Natl. Cancer Inst., 92: 826-832, 2000.[Abstract/Free Full Text]
- Ong D. E., Newcomer M. E., Chytil F. Cellular retinoid-binding proteins Sporn M. B. Roberts A. B. Goodman D. S. eds. . The Retinoids: Biology, Chemistry and Medicine, Ed. 2 283-317, Raven Press New York 1994.
- Vogel S., Mendelsohn C. L., Mertz J. R., Piantedosi R., Waldburger C., Gottesman M. E., Blaner W. S. Characterization of a new member of the fatty acid-binding protein family that binds all-trans-retinol. J. Biol. Chem., 276: 1353-1360, 2001.[Abstract/Free Full Text]
- Folli C., Calderone V., Ottonello S., Bolchi A., Zanotti G., Stoppini M., Berni R. Identification, retinoid binding, and X-ray analysis of a human retinol-binding protein. Proc. Natl. Acad. Sci. USA, 98: 3710-3715, 2001.[Abstract/Free Full Text]
- Ghyselinck N. B., Bavik C., Sapin V., Mark M., Bonnier D., Hindelang C., Dierich A., Nilsson C. B., Hakansson H., Sauvant P., Azais-Braesco V., Frasson M., Picaud S., Chambon P. Cellular retinol-binding protein I is essential for vitamin A homeostasis. EMBO J., 18: 4903-4914, 1999.[Medline]
- Kuppumbatti Y. S., Bleiweiss I. J., Mandeli J. P., Waxman S., Mira-Y-Lopez R. Cellular retinol-binding protein expression and breast cancer. J. Natl. Cancer Inst., 92: 475-480, 2000.[Abstract/Free Full Text]
- Esteller M., Cordon-Cardo C., Corn P. G., Meltzer S. J., Pohar K. S., Watkins D. N., Capella G., Peinado M. A., Matias-Guiu X., Prat J., Baylin S. B., Herman J. G. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res., 61: 2816-2821, 2001.[Abstract/Free Full Text]
- Esteller M., Risques R. A., Toyota M., Capella G., Moreno V., Peinado M. A., Baylin S. B., Herman J. G. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res., 61: 4689-4692, 2001.[Abstract/Free Full Text]
- Esteller M., Corn P. G., Baylin S. B., Herman J. G. A gene hypermethylation profile of human cancer. Cancer Res., 61: 3225-3229, 2001.[Abstract/Free Full Text]
- The EPIC group of Spain Validity and reproducibility of a diet history questionnaire in Spain. I. Foods. Int. J. Epidemiol., 26 (Suppl. 1): s91-s99, 1997.
- Willet W. C., Howe G. R., Kushi L. H. Adjustment for total energy intake in epidemiological studies. Am. J. Clin. Nutr., 65 (Suppl.): 1220s-1228s, 1997.
- Herman J. G., Graff J. R., Myohanen S., Nelkin B. D., Baylin S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.[Abstract/Free Full Text]
- Lotan R., Xu X. C., Lippman S. M., Ro J. Y., Lee J. S., Lee J. J., Hong W. K. Suppression of retinoic acid receptor-ß in premalignant oral lesions and its up-regulation by isotretinoin. N. Engl. J. Med., 332: 1405-1410, 1995.[Abstract/Free Full Text]
- Whang-Peng J., Kao-Shan C. S., Lee E. C., Bunn P. A., Carney D. N., Gazdar A. F., Minna J. D. Specific chromosome defect associated with human small-cell lung cancer: deletion 3p(14–23). Science (Wash. DC), 215: 181-182, 1982.[Abstract/Free Full Text]
- Maitra A., Wistuba I. I., Washington C., Virmani A. K., Ashfaq R., Milchgrub S., Gazdar A. F., Minna J. D. High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss. Am. J. Pathol., 159: 119-130, 2001.[Abstract/Free Full Text]
- Bavik C., Ward S. J., Ong D. E. Identification of a mechanism to localize generation of retinoic acid in rat embryos. Mech. Dev., 69: 155-167, 1997.[Medline]
- Easwaran V., Pishvaian M., Salimuddin, Byers S. Cross-regulation of ß-catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol., 9: 1415-1418, 1999.[Medline]
- Kuppumbatti Y. S., Rexer B., Nakajo S., Nakaya K., Mira-y-Lopez R. CRBP suppresses breast cancer cell survival and anchorage independent growth. Oncogene, 20: 7413-7419, 2001.[Medline]
- Veronesi U., De Palo G., Marubini E., Costa A., Formelli F., Mariani L., Decensi A., Camerini T., Del Turco M. R., Di Mauro M. G., Muraca M. G., Del Vecchio M., Pinto C., D’Aiuto G., Boni C., Campa T., Magni A., Miceli R., Perloff M., Malone W. F., Sporn M. B. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J. Natl. Cancer Inst., 91: 1847-1856, 1999.[Abstract/Free Full Text]
This article has been cited by other articles:
|
|
|
|
 
K. Van Beneden, L. A. van Grunsven, C. Geers, M. Pauwels, A. Desmouliere, D. Verbeelen, A. Geerts, and C. Van den Branden
CRBP-I in the renal tubulointerstitial compartment of healthy rats and rats with renal fibrosis
Nephrol. Dial. Transplant.,
July 10, 2008;
(2008)
gfn290v3.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T M Murphy, A S Perry, and M Lawler
The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer
Endocr. Relat. Cancer,
March 1, 2008;
15(1):
11 - 25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Y. Lee, S. M. Patton, R. J. Henderson, and J. R. Connor
Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE
FASEB J,
February 1, 2007;
21(2):
564 - 576.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-f. Wang, D. Z. Qian, M. Ren, Y. Kato, Y. Wei, L. Zhang, Z. Fansler, D. Clark, O. Nakanishi, and R. Pili
Epigenetic Modulation of Retinoic Acid Receptor {beta}2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma
Clin. Cancer Res.,
May 1, 2005;
11(9):
3535 - 3542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lotan
A Crucial Role for Cellular Retinol-Binding Protein I in Retinoid Signaling
J Natl Cancer Inst,
January 5, 2005;
97(1):
3 - 4.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. F. Farias, D. E. Ong, N. B. Ghyselinck, S. Nakajo, Y. S. Kuppumbatti, and R. Mira y Lopez
Cellular Retinol-Binding Protein I, a Regulator of Breast Epithelial Retinoic Acid Receptor Activity, Cell Differentiation, and Tumorigenicity
J Natl Cancer Inst,
January 5, 2005;
97(1):
21 - 29.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Jeronimo, R. Henrique, M. O. Hoque, E. Mambo, F. R. Ribeiro, G. Varzim, J. Oliveira, M. R. Teixeira, C. Lopes, and D. Sidransky
A Quantitative Promoter Methylation Profile of Prostate Cancer
Clin. Cancer Res.,
December 15, 2004;
10(24):
8472 - 8478.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takahashi, N. Shivapurkar, E. Riquelme, H. Shigematsu, J. Reddy, M. Suzuki, K. Miyajima, X. Zhou, B. N. Bekele, A. F. Gazdar, et al.
Aberrant Promoter Hypermethylation of Multiple Genes in Gallbladder Carcinoma and Chronic Cholecystitis
Clin. Cancer Res.,
September 15, 2004;
10(18):
6126 - 6133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Jeronimo, R Henrique, J Oliveira, F Lobo, I Pais, M R Teixeira, and C Lopes
Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer
J. Clin. Pathol.,
August 1, 2004;
57(8):
872 - 876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Takahashi, N. Shivapurkar, J. Reddy, H. Shigematsu, K. Miyajima, M. Suzuki, S. Toyooka, S. Zochbauer-Muller, J. Drach, G. Parikh, et al.
DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies
Clin. Cancer Res.,
May 1, 2004;
10(9):
2928 - 2935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. Gazdar, K. Miyajima, J. Reddy, U. G. Sathyanarayana, H. Shigematsu, M. Suzuki, T. Takahashi, and N. Shivapurkar
Molecular Targets for Cancer Therapy and Prevention
Chest,
May 1, 2004;
125(5_suppl):
97S - 101S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Villar-Garea, M. F. Fraga, J. Espada, and M. Esteller
Procaine Is a DNA-demethylating Agent with Growth-inhibitory Effects in Human Cancer Cells
Cancer Res.,
August 15, 2003;
63(16):
4984 - 4989.
[Abstract]
[Full Text]
[PDF]
|
|
|
Top
ABSTRACT
INTRODUCTION
